Integra LifeSciences Holdings Co. (NASDAQ:IART – Get Rating) – Stock analysts at Jefferies Financial Group decreased their Q3 2022 earnings per share (EPS) estimates for Integra LifeSciences in a research note issued on Wednesday, April 27th. Jefferies Financial Group analyst F. Pinal now expects that the life sciences company will earn $0.84 per share for the quarter, down from their prior forecast of $0.87. Jefferies Financial Group also issued estimates for Integra LifeSciences’ FY2024 earnings at $4.43 EPS.
Several other equities analysts also recently commented on IART. Truist Financial downgraded shares of Integra LifeSciences from a “buy” rating to a “hold” rating and cut their price target for the company from $72.00 to $71.00 in a report on Wednesday, April 13th. StockNews.com cut shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Friday, April 22nd. Piper Sandler lowered their price target on shares of Integra LifeSciences from $72.00 to $66.00 in a research report on Wednesday, February 23rd. Finally, Bank of America increased their target price on shares of Integra LifeSciences from $55.00 to $65.00 and gave the company an “underperform” rating in a research report on Tuesday, January 18th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $75.56.
Integra LifeSciences (NASDAQ:IART – Get Rating) last announced its quarterly earnings results on Wednesday, April 27th. The life sciences company reported $0.74 EPS for the quarter, topping the consensus estimate of $0.68 by $0.06. Integra LifeSciences had a net margin of 10.96% and a return on equity of 16.93%. The business had revenue of $376.60 million for the quarter, compared to analysts’ expectations of $362.19 million. During the same quarter in the previous year, the company earned $0.69 EPS. The business’s quarterly revenue was up 4.6% compared to the same quarter last year.
Several large investors have recently bought and sold shares of the company. CIBC Asset Management Inc lifted its stake in shares of Integra LifeSciences by 4.7% in the fourth quarter. CIBC Asset Management Inc now owns 3,558 shares of the life sciences company’s stock worth $238,000 after buying an additional 160 shares in the last quarter. Advisor Group Holdings Inc. grew its holdings in Integra LifeSciences by 2.4% during the 3rd quarter. Advisor Group Holdings Inc. now owns 7,376 shares of the life sciences company’s stock worth $506,000 after acquiring an additional 175 shares in the last quarter. State of Michigan Retirement System lifted its position in shares of Integra LifeSciences by 1.1% during the 4th quarter. State of Michigan Retirement System now owns 18,466 shares of the life sciences company’s stock worth $1,237,000 after buying an additional 200 shares during the last quarter. NorthCrest Asset Manangement LLC lifted its position in shares of Integra LifeSciences by 1.5% during the 1st quarter. NorthCrest Asset Manangement LLC now owns 13,800 shares of the life sciences company’s stock worth $887,000 after buying an additional 200 shares during the last quarter. Finally, Campbell Newman Asset Management Inc. raised its position in Integra LifeSciences by 1.9% in the 1st quarter. Campbell Newman Asset Management Inc. now owns 12,743 shares of the life sciences company’s stock valued at $819,000 after purchasing an additional 243 shares during the last quarter. 90.98% of the stock is currently owned by hedge funds and other institutional investors.
In other news, COO Glenn Coleman sold 6,268 shares of the firm’s stock in a transaction dated Monday, April 4th. The shares were sold at an average price of $66.04, for a total value of $413,938.72. Following the transaction, the chief operating officer now directly owns 41,288 shares of the company’s stock, valued at $2,726,659.52. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Tru St Partnership, L.P. sold 150,000 shares of the firm’s stock in a transaction dated Wednesday, March 23rd. The stock was sold at an average price of $64.67, for a total transaction of $9,700,500.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 231,268 shares of company stock worth $15,050,939. Insiders own 4.20% of the company’s stock.
About Integra LifeSciences (Get Rating)
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services.
- Get a free copy of the StockNews.com research report on Integra LifeSciences (IART)
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
- Iridium Communications Stock is Ready to Return to Orbit
- There’s An Institutional Floor In Keurig Dr. Pepper
- Ford Falls Despite Optimistic Outlook
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.